|Title:||Adrenalectomy Improves the Long-Term Risk of End-Stage Renal Disease and Mortality of Primary Aldosteronism||Authors:||Chen Y.-Y.
You-Hsien Hugo Lin
|Issue Date:||2019||Publisher:||Oxford University Press||Journal Volume:||3||Journal Issue:||6||Start page/Pages:||1110-1126||Source:||Journal of the Endocrine Society||Abstract:||
Objective: Primary aldosteronism (PA) is a common cause of secondary hypertension, and the longterm effect of excess aldosterone on kidney function is unknown. Patients and Methods: We used a longitudinal population database from the Taiwan National Health Insurance system and applied a validated algorithm to identify patients with PA diagnosed between 1997 and 2009. Results: There were 2699 patients with PA recruited, of whom 761 patients with an aldosteroneproducing adenoma (APA) were identified. The incidence rate of end-stage renal disease (ESRD) was 3% in patients with PA after targeted treatments and 5.2 years of follow-up, which was comparable to the rate in controls with essential hypertension (EH). However, after taking mortality as a competing risk, we found a significantly lower incidence of ESRD when comparing patients with PA vs EH [subdistribution hazard ratio (sHR), 0.38; P50.007] and patients with APA vs EH(sHR 0.55; P50.021) after adrenalectomy; however, we did not see similar results in groups with mineralocorticoid receptor antagonist (MRA)-treated PA vs EH. There was also a significantly lower incidence of mortality in groups with PA and APA who underwent adrenalectomy than among EH controls (P , 0.001). Conclusion: Regarding incident ESRD, patients with PA were comparable to their EH counterparts after treatment. After adrenalectomy, patients with APA had better long-term outcomes regarding progression to ESRD and mortality than hypertensive controls, but MRA treatments did not significantly affect outcome. Copyright ? 2019 Endocrine Society.
|ISSN:||2472-1972||DOI:||10.1210/js.2019-00019||SDG/Keyword:||mineralocorticoid antagonist; spironolactone; adrenalectomy; adult; age; Article; Charlson Comorbidity Index; cohort analysis; comorbidity; comparative study; controlled study; end stage renal disease; essential hypertension; female; follow up; human; longitudinal study; major clinical study; male; middle aged; mortality risk; primary hyperaldosteronism; priority journal; risk assessment; treatment response
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.